Clinical trial · Interventional
Comparison of an Initial Active Follow-up and Therapeutic Care on Functional Outcome and Quality of Life in Patients With Head and Neck Paragangliomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Head and neck paragangliomas (HNPGs) are predominantly non-secreting, benign and slow-growing tumors. Although most patients remain asymptomatic, up to 30% develop symptoms related to local tumor growth and fewer than 5-10% develop metastatic disease. Surgery has long been considered the standard treatment, while radiotherapy and active surveillance represent alternative management strategies. Treatment-related morbidity and impaired quality of life have been reported in patients with HNPGs; however, the impact of immediate intervention compared with an initial active surveillance strategy has not been prospectively evaluated. This multicenter randomized controlled trial aims to compare active surveillance with immediate intervention in patients with newly diagnosed carotid or vagal paragangliomas. The study hypothesis is that an initial active surveillance strategy increases the time before functional outcome deterioration, particularly ENT-related symptoms, while not resulting in a higher complication rate when treatment is subsequently performed. Eligible patients will undergo baseline assessment including a specialized ENT examination to evaluate cranial nerve function and cervical MRI (or contrast-enhanced CT when MRI is contraindicated) to confirm tumor location, size, and the absence of lymphadenopathy or atypical imaging features. After providing written informed consent, participants will be centrally randomized in a 1:1 ratio, stratified by study center and tumor location, to either active surveillance or immediate intervention. Patients assigned to active surveillance will undergo regular clinical and radiological follow-up, with treatment initiated only if disease progression or symptom development warrants intervention. Patients assigned to immediate intervention will receive surgery or radiotherapy according to multidisciplinary team recommendations and local practice, within six months after randomization. Patients who decline participation in the randomized trial, as well as those who are not eligible for randomization, may be offered participation in a parallel observational study collecting clinical, imaging, treatment and outcome data according to routine practice. Patient quality of life will also be assessed throughout the study (experimental and observational) using validated questionnaires.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Paragangliomas | Paraganglioma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Active follow-up | Other | — | UNRESOLVED |
| Radiation | Radiation | — | UNRESOLVED |
| Surgery | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Active follow-up
- interventionNames
- Other: Active follow-up
- type
- ACTIVE_COMPARATOR
- label
- Treatment
- description
- Patients will be treated by surgery or radiation. The choice between these 2 options is left to the discretion of the investigator and the patient.
- interventionNames
- Procedure: Surgery
- Radiation: Radiation
Primary outcomes (1)
- measure
- Time to functional outcome deterioration
- timeFrame
- From baseline to 5 years maximum
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients ≥ 18 years-old, * Diagnosis of carotid or vagal HNPG with a largest diameter more than 10 mm * Diagnosis confirmed by imaging reading (MRI of CT scan) from less than 6 months, * Study eligibility validated in multidisciplinary discussion, * Patient followed in the reference center, * Preliminary written informed consent before any study-specific intervention Exclusion Criteria: * Patient with initial nerve palsy due to the evaluated HNPG, * Patient with non-typical presentation suggestive of aggressiveness (tumor pain, atypical imaging, suspicious lymphadenopathy), * Malignant HNPG identified by extra cervical lesion on metabolic imaging, * More than one HNPG at inclusion * Secreting HNPG defined as plasma or urine metanephrine or normetanephrine more than 2 times ULN, * Patient already treated with cervical radiotherapy, * Patient already treated with systemic therapy for another pheochromocytoma or paraganglioma, * Patient with another evolutive disease or other condition resulting on a life expectancy of less than 5 years at the investigator's discretion, * Patient unable or unwilling to be treated at the study center * Patients currently enrolled in another interventional study including investigational medicinal products or device, * Female patients who are pregnant, lactating or women of child-bearing potential without highly effective methods of contraception * Persons deprived of their liberty by a judicial or administrative decision * Persons under psychiatric care * Persons admitted to a health or social institution for purposes other than research * Adults subject to a legal protection measure (guardianship, curatorship) * Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
References
Publications (0)
Data not yet available